Medical aesthetic dermatology is expanding rapidly in response to increasing demand for minimally invasive interventions and advanced topical therapies. The clinical performance of conventional dermatological formulations is frequently limited by inadequate skin penetration, poor stability of active ingredients, rapid degradation, and dose-related adverse effects. Nanotechnology-based drug formulation and delivery systems offer a translational solution to these challenges by enabling targeted, controlled, and sustained delivery of bioactive compounds to specific skin layers and appendages. Nanoscale carriers—including lipid-based systems, polymeric nanoparticles, nanoemulsions, and inorganic or hybrid nanomaterials—enhance dermal and follicular deposition, improve physicochemical stability, and modulate release kinetics of therapeutic and cosmeceutical agents. These mechanisms have facilitated improved outcomes across key aesthetic indications, including skin rejuvenation, pigmentary disorders, acne, hair restoration, and injectable aesthetic interventions. Emerging clinical and preclinical evidence suggests improved local efficacy and potentially reduced irritation and systemic exposure compared with conventional formulations, although further well-controlled clinical studies are required to confirm these benefits. Safety, toxicological behavior, and regulatory considerations remain critical determinants of successful clinical translation, particularly with respect to long-term exposure and nanoparticle–skin interactions. Integration of pharmacological mechanisms with clinical performance highlights the growing role of nanotechnology in redefining therapeutic strategies within medical aesthetic dermatology and supports its continued development within evidence-based translational pharmacology frameworks.
Wang et al. (Wed,) studied this question.